Pfizer “Approvable” Streak Continues With Second letter For Anidulafungin
This article was originally published in The Pink Sheet Daily
Executive Summary
The antifungal agent’s second approvable letter is for an esophageal candidiasis indication.
You may also be interested in...
Pfizer To Spring Forward With Eraxis Launch
Anidulafungin is approved for treatment of esophageal candidiasis and candidemia.
Pfizer To Spring Forward With Eraxis Launch
Anidulafungin is approved for treatment of esophageal candidiasis and candidemia.
Pfizer’s Dalbavancin “Approvable”
FDA issued an "approvable" letter for Pfizer's lipoglycopeptide antibiotic dalbavancin Sept. 21, the agency said